Search results
Author(s):
Zuzana Kaifoszova
,
Petr Widimsky
Added:
3 years ago
Primary percutaneous coronary intervention (PPCI) and thrombolysis (TL) represent two alternative reperfusion strategies for ST-elevation acute myocardial infarction (STEMI) patients. In many randomised clinical trials,1 PPCI has been shown to be superior to TL in reducing mortality, re-infarction and stroke. These benefits are linked with a much higher early mechanical reperfusion rate (90 %,…
View more
Author(s):
Akshyaya Pradhan
,
Monika Bhandari
,
Pravesh Vishwakarma
,
et al
Added:
3 years ago
Author(s):
Darren Mylotte
,
Ruben LJ Osnabrugge
,
Giuseppe Martucci
,
et al
Added:
3 years ago
Transcatheter aortic valve implantation (TAVI) has emerged as a safe and efficacious treatment in patients with symptomatic severe aortic stenosis (AS) at high- or excessive-risk for surgical aortic valve replacement.1,2 More recently, TAVI technology has been extended to treating high-risk patients with failing aortic or mitral surgical bioprosthetic valves, bicuspid aortic stenosis, pure aortic…
View more
Primary Angioplasty for Acute Myocardial Infarction and the Emerging Role of Renal Insufficiency
Author(s):
Giancarlo Marenzi
,
Antonio L Bartorelli
Added:
3 years ago
Article
Author(s):
Petr Kala
Added:
3 years ago
Patients suffering acute myocardial infarction with ST-segment elevation (STEMI) require full attention of the whole STEMI network to save their lives and to improve the quality of life after a heart attack. Close cooperation among all stakeholders on a national and regional level has to be established. The emergency medical service (EMS) and direct transportation to the 24 hours a day, seven…
View more
Author(s):
Derek P Chew
,
Harvey D White
Added:
3 years ago
Effective translation of reperfusion therapy to mortality reductions in ST-segment elevation myocardial infarction (STEMI) remains both time-critical in its implementation and dependent on optimal antithrombotic therapy. Innumerable clinical studies have explored several antithrombin and antiplatelet therapies in the immediate management of STEMI. With the wide array of the therapies now…
View more
Author(s):
Francesco Summaria
,
Marina Mustilli
,
Chiara Lanzillo
,
et al
Added:
3 years ago
Coronary thrombosis is the leading cause of ST elevation acute myocardial infarction (AMI). Related to a more frequent platelets abnormalities and ‘floating’ growing thrombi, distal embolization often occur during primary percutaneous coronary intervention (PCI) stenting1,2 especially in coronary artery ectasia (CAE), causing a large variability in coronary flow pattern. This variability is…
View more
Author(s):
Nilesh Pareek
,
Peter Kordis
,
Ian Webb
,
et al
Added:
3 years ago
Out-of-hospital cardiac arrest (OHCA) is defined as the sudden absence of cardiac mechanical contractility with loss of signs of circulation that occurs within a community setting.1 OHCA affects more than half a million patients globally per year and is one the leading causes of death in developing countries.2 In the US, OHCA affects 350,000 patients per year and is the third leading cause of…
View more
Natriuretic Peptides - A Review
Author(s):
PO Collinson
Added:
3 years ago
Article
Author(s):
Krishnaraj S Rathod
,
Stephen M Hamshere
,
Tawfiq R Choudhury
,
et al
Added:
3 years ago
Primary percutaneous coronary intervention (PPCI) is the optimal treatment strategy for restoring coronary blood flow in the infarct related artery (IRA) and salvaging myocardium in patients with ST elevation myocardial infarction (STEMI).1,2 Despite this, PPCI fails to restore optimal myocardial perfusion in up to 40 % of patients despite restoring epicardial artery patency as evidenced by…
View more